Management of Liver Donor with Positive QuantiFERON-TB Gold and Normal Chest X-ray

Critical Understanding: Donors as Vectors for TB Transmission

The liver donor should receive treatment for latent tuberculosis infection (LTBI) with 9 months of isoniazid prior to organ procurement, as donors with latent TB can transmit Mycobacterium tuberculosis through the liver graft itself, according to the Journal of Hepatology 1
Active tuberculosis in donors is an absolute contraindication to organ donation, but donors with untreated latent TB can be used if recipients receive appropriate prophylaxis, as stated in the Journal of Hepatology 1

The positive QuantiFERON-TB Gold test indicates infection with Mycobacterium tuberculosis but does not distinguish between active and latent disease, as noted in Praxis Medical Insights: Practical Summaries of Clinical Guidelines 2
A thorough clinical assessment for TB symptoms including fever, night sweats, weight loss, cough, and hemoptysis should be performed to definitively exclude active disease, according to the Journal of Hepatology and Praxis Medical Insights: Practical Summaries of Clinical Guidelines 1, 2

Administer 9 months of isoniazid (300 mg daily) with pyridoxine (vitamin B6) supplementation prior to organ procurement, as recommended by the Journal of Hepatology and Praxis Medical Insights: Practical Summaries of Clinical Guidelines 2, 3
Isoniazid is effective in preventing donor-derived tuberculosis, which typically becomes symptomatic within 3 months post-transplant if untreated, according to the Journal of Hepatology 1

Even with treated donor LTBI, consider prophylactic isoniazid for the recipient given the high-risk nature of donor-derived TB, as suggested by the Journal of Hepatology 1
Monitor recipients closely for atypical presentations of TB, as extrapulmonary tuberculosis occurs more frequently in transplant patients than in the general population, according to the Journal of Hepatology 3
Early recognition and treatment of active TB significantly improves survival, as noted in the Journal of Hepatology 1

Do not repeat QuantiFERON testing after treatment completion, as the test may remain positive even after successful LTBI treatment, as stated in the Journal of the American Academy of Dermatology and Praxis Medical Insights: Practical Summaries of Clinical Guidelines 2, 4, 5, 6